These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 16192793)
21. Excessive requirement for heparin during cardiac surgery. Chung F; David TE; Watt J Can Anaesth Soc J; 1981 May; 28(3):280-2. PubMed ID: 7237224 [TBL] [Abstract][Full Text] [Related]
22. The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Bowers J; Ferguson JJ Clin Cardiol; 1994 Jul; 17(7):357-61. PubMed ID: 8088021 [TBL] [Abstract][Full Text] [Related]
23. [Measurement of activated clotting time during cardiopulmonary bypass in infective endocarditis patients]. Jiang L; Yu JF Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):167-9. PubMed ID: 17344611 [TBL] [Abstract][Full Text] [Related]
24. Con: The Hepcon HMS Should Not Be Used Instead of Traditional Activated Clotting Time to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass. Gilly G; Trusheim J J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1730-1732. PubMed ID: 27751763 [No Abstract] [Full Text] [Related]
25. Activated clotting time during cardiopulmonary bypass: is repetition necessary during open heart surgery? Neema PK; Sinha PK; Rathod RC Asian Cardiovasc Thorac Ann; 2004 Mar; 12(1):47-52. PubMed ID: 14977742 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass. Terrell MR; Walenga JM; Koza MJ; Pifarré R Ann Thorac Surg; 1996 Aug; 62(2):506-11. PubMed ID: 8694614 [TBL] [Abstract][Full Text] [Related]
27. Bivalirudin for anticoagulation during hypothermic cardiopulmonary bypass and recombinant factor VIIa for iatrogenic coagulopathy. Nagle EL; Tsu LV; Dager WE Ann Pharmacother; 2011 Sep; 45(9):e47. PubMed ID: 21862711 [TBL] [Abstract][Full Text] [Related]
28. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293 [TBL] [Abstract][Full Text] [Related]
30. Challenging Argatroban Management of a Child on Extracorporeal Support and Subsequent Heart Transplant. Latham GJ; Jefferis Kirk C; Falconer A; Dickey R; Albers EL; McMullan DM Semin Cardiothorac Vasc Anesth; 2016 Jun; 20(2):168-74. PubMed ID: 26721808 [TBL] [Abstract][Full Text] [Related]
31. Pro: The Hepcon HMS Should Be Used Instead of Traditional Activated Clotting Time (ACT) to Dose Heparin and Protamine for Cardiac Surgery Requiring Cardiopulmonary Bypass. Ural K; Owen C J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1727-1729. PubMed ID: 27641953 [No Abstract] [Full Text] [Related]
32. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time. Pötzsch B; Madlener K; Seelig C; Riess CF; Greinacher A; Müller-Berghaus G Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403 [TBL] [Abstract][Full Text] [Related]
33. Activated clotting time for control of anticoagulation during surgery. Lefemine AA; Lewis M Am Surg; 1985 May; 51(5):274-8. PubMed ID: 3994170 [TBL] [Abstract][Full Text] [Related]
34. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Avidan MS; Levy JH; Scholz J; Delphin E; Rosseel PM; Howie MB; Gratz I; Bush CR; Skubas N; Aldea GS; Licina M; Bonfiglio LJ; Kajdasz DK; Ott E; Despotis GJ Anesthesiology; 2005 Feb; 102(2):276-84. PubMed ID: 15681940 [TBL] [Abstract][Full Text] [Related]
35. Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass. Nicholson SC; Keeling DM; Sinclair ME; Evans RD Br J Anaesth; 2001 Dec; 87(6):844-7. PubMed ID: 11878684 [TBL] [Abstract][Full Text] [Related]
36. Heparin resistance, antithrombin III treatment, and activated clotting time values. Kanbak M Anesth Analg; 1998 Nov; 87(5):1215. PubMed ID: 9806721 [No Abstract] [Full Text] [Related]
37. Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. Jabr K; Johnson JH; McDonald MH; Walsh DL; Martin WD; Johnson AC; Pickett JM; Shantha-Martin U J Extra Corpor Technol; 2004 Jun; 36(2):174-7. PubMed ID: 15334761 [TBL] [Abstract][Full Text] [Related]
38. A reevaluation of heparin requirements for cardiopulmonary bypass. Cardoso PF; Yamazaki F; Keshavjee S; Schaefers HJ; Hsieh CM; Wang LS; Glynn MF; Patterson GA; Cooper JD J Thorac Cardiovasc Surg; 1991 Jan; 101(1):153-60. PubMed ID: 1986159 [TBL] [Abstract][Full Text] [Related]
39. Cardiopulmonary bypass for complex cardiac surgery using bivalirudin anticoagulation in a patient with heparin antibodies. Huebler M; Koster A; Buz S; Boettcher W; Hetzer R; Kuppe H; Dyke CM J Card Surg; 2006; 21(3):286-8. PubMed ID: 16684064 [TBL] [Abstract][Full Text] [Related]
40. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy. Kurec AS; Morris MW; Davey FR Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]